Here is a 2017 article that might help some appreciate the work that led to the Nobel & the limited success that Ipilimumab has shown. In particular, the disappointing results for PCa.
technologyreview.com/s/6040...
There are a couple of references to PCa:
"... Allison says by that time he was aware of his drug’s limitations. It didn’t help everyone, and it didn’t work in most cancers. And if he needed a reminder of the stakes, it came in 2005, when Allison’s brother succumbed to prostate cancer after eight years. The same year, doctors found early-stage cancer in Allison’s own prostate. He had surgery rather than chance drug treatment."
...
"... I saw Allison huddled over an iPad with another scientist, discussing some of the most recent findings he, Blando, and Sharma have made using their platform. They have been studying prostate cancer, in which no checkpoint drug yet seems to work. “What we found was that prostate cancer is almost a desert immunologically,” Allison says. “It’s a very cold tumor. There’s not much in there.” But Blando’s microscope has revealed that two drugs together might make the difference. Yervoy {Ipilimumab}, he found, is necessary to drive T cells into the tumor, while the addition of a PD-1 drug makes sure they start killing. On the basis of these results and further research, Sharma and Allison convinced Bristol-Myers to combine the drugs in a clinical trial for advanced prostate cancer."
clinicaltrials.gov/ct2/show...
-Patrick
Is anyone familiar with the GUN trial?
Jim Marshall retires but Australian links on JimJimJimJim.com
Complementary Therapies - Your Experience?
Flaxseed -pro or con or does it depend on your status
